Search results

@Snow Leopard you'll be relieved/reassured ;) to know that: "He [AstraZeneca chief] added he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5%."...

If this is significant in ME, then I assume that it would turn up in a gene expression study (microRNA) and/or genome-wide association study (GWAS) - correct? @Simon M

There's a Christmas post on MEAction Global by Janet Defoe/Whitney re Aripiprazole/Abilify - OMF are looking at the underlying mechanism for Aripiprazole/Abilify

Watching TV late last night (UK) and the BBC 24 hour news said that the Oxford vaccine would be approved in days!

Heard the same, from a neighbour who is a GP, i.e. the UK is about to start vaccinating with the Oxford vaccine (January). Not surprised about the "no choice" who would choose Oxford over the other 2?

Could you post a link to the (New York?) Times article - thanks.

Are there any more (cheaper) RNA vaccines reporting in the near future?

Maybe linked to the point @Snow Leopard made i.e. the Oxford vaccine might not be effective enough to achieve herd immunity (RNA vaccines are)

Particularly true when the vaccine is already being rolled out; i.e. reduce the level of transmission and get on with vaccinating people/ending the pandemic.

Seems the Moderna vaccine is stable*; however, I wonder if this will come down to cost - Moderna $25 - Oxford $2.5 -- 10X. Also, apparently they can tweak these RNA vaccines to make them more (temperature) stable. *"Refrigeration Storage: After thawing, to facilitate storage at points of...

Thank you @Snow Leopard if the new variant has higher transmissibility (OK that's disputed) then the vaccine may need to be more effective i.e. to achieve herd immunity.

I wonder if EU has rules re this; however, if you're not subject to an "external" regulatory framework then I guess that leaves flexibility.

@Snow Leopard @Jonathan Edwards rumour mill is that the UK will approve the Oxford vaccine (on 28th December). Is there a phase 3 trial ongoing in the US on this vaccine? Grateful for any info.

To me that logic also applies to the post Lyme disease community and possibly a host of other post --- disease. One of the difficulties has been trying to get folks in other groups (often quite arbitrarily self allocated to those groups) to work with people with ME. Also, I recall advice to...

Good point, that is the key thing i.e. what they did & the results --- but there's commercial interest.

I was not suggesting that we should approve the Oxford vaccine on the basis that we need to vaccinate the population and get back to "normal". I was simply concerned that we only have access to enough Pfizer/Moderna to vaccinate 25 million people (population 100 million ish). I think @Jonathan...

Maybe there are other factors at play here e.g. the folks who benefit from the current system are important to BMJ. But yes, if this is crap then highlight that.

Apologies, to quote a former co-worker --- let's look at the big picture here --- how will this affect me! If the Oxford vaccine doesn't come through then the UK has access to a limited amount of the other 2 (RNA) vaccines: 40 million Pfizer 7 million Moderna so that's enough to vaccinate 25%...

Seems that there's been a bit of progress i.e. Phair's found that they can replicate the trap in "human monocyte-derived macrophages" and [Davis] in yeast cells expressing the human IDO1 gene. Problem seems to be measuring intracellular tryptophan levels and demonstrating the trap in brain...

Thanks @Jonathan Edwards seemed (to me) to be an interesting hypothesis since my wife has syringomyelia (voids in the spinal column caused by excess pressure) and one of our children has severe (i.e. disabling) fatigue. Probably any theory which is attractive/resonates should be treated with...